The TIGIT trail has proved to be a tricky ... which combines its PD-1 inhibitor Opdivo (nivolumab) with LAG-3 drug relatlimab. That is approved for melanoma, but failed a phase 3 trial in MSS ...

BMS, which snapped up a TIGIT class cancer drug from Agenus ... Tumours fight off the attack by stimulating LAG-3 and PD-1, causing the white blood cells to become exhausted.

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

It was found that in NSCLC, intratumoral Tregs cells presented increased expression of inhibitory molecules including LAG-3, CTLA-4, and PD-1. NSCLC is the most common type of lung cancer ...